Israeli pharmaceutical company Protalix has signed a development deal with pharmaceutical giant Pfizer, for the continuation of development of its Elelyso drug. According to the agreement, Portalix will continue to conduct the clinical trials for the drug, which is currently being tested on children and adults. As part of the agreement, the Israeli company will receive up to $8.3 million for milestone achievements.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Red Algae Can Treat Wounds And Infections
January 26, 2023

Freight Planner Lists on Nasdaq And Raises $80M
January 26, 2023

$6M Investment For “Lettuce Milk” Startup
January 25, 2023

Israel Has World’s Best Value Internet
January 25, 2023
Facebook comments